How many more jury trials are yet to come? |
How sad are we ! |
You don't do anything Abdulla except pit in negative comments and troll gak . Sad really |
I buy when you dive,so dive,dive,dive . |
05 Aug 2024 08:51AMGSK : BERNSTEIN RAISES TARGET PRICE TO 2,610P FROM 2,560PThis news story contains no content |
Movement in the rate of the £ ? |
Yesterday it goes up when the market is undergoing a wider sell off. Today, on a "blue day" and with a hint of good news it goes down! Absolutely unfathomable! |
Will the share price not be affected by the global market meltdown yday? So good xantac news offset by this ? |
It seems the fat lady hasn't sung yet |
Think the market doesn't see any "read across" but I suspect it would have if GSK had lost |
Doesn't look like good news to the markets |
Over £16 @ the open? |
Nice to see a court case win, as it was news of these collective challenges that sent the share price heading south from 1800..Looks like the wider market is on for a rebound too after the sell off Friday/Monday, could be an interesting day.. :o) |
Seems like good news.. |
Crazy disparity but I suppose Barclays is nearer the average consensus |
Barclays cuts target price to 1650p from 1725p. Bernstein raises target price to 2610p from 2560p ...??! |
 From the IC.At first sight, the market seemed to shrug off what were objectively decent results for drugmaker GSK (GSK) as the now pure play pharmaceutical company finds its feet and restocks what had become a threadbare research & development pipeline. Getting more value out of hard-to-copy medicines is a priority for GSK, and one where it lags its highly valued competitor AstraZeneca (AZN), but first it has a battalion of troubles to deal with. It is the state of litigation which has given investors a dyspeptic ulcer. The prospect of the company facing long rounds of litigation over its Zantac reflux medicine, with suits alleging its cancer-causing properties having been filed in numerous jurisdictions, was enough to crash the shares earlier this year the main problem being the currently unquantifiable cost of the saga.There is nothing new to report on this front, other than the company's legal costs in relation to this topic have increased, although it does not break these out of the cost of individual litigation.Unsurprisingly, chief executive Dame Emma Walmsley was keen to accentuate the positive: "Sales grew in all areas, with speciality medicines in particular benefiting from new product launches in oncology and HIV. In R&D, so far this year, we have secured approvals or filings for 10 major opportunities and reported positive data from seven phase III trials".RSV jab restrictions heap more uncertainty on GSKThe company's core reported operating profits, which strips out inconvenient costs such as litigation to which pharmaceutical companies are notoriously vulnerable, were 16 per cent higher for the half at £4.95bn. This was marginally ahead of consensus forecasts, which meant an upgrade in expectations for operating profit growth to a range 11 to 13 per cent.However, the market also seemed to cotton to GSK's higher contingent liability charges of £1.06bn, compared with a credit of £0.46bn last year. Fair value losses of £35mn were booked for GSK's ongoing share of its Haleon spin-out, as well to reflect the longer-term prospects for its vaccines business and various milestones that it will need to pay its development partners.In addition to its woes, Deutsche Bank points out that there are questions over how effectively GSK can bridge the patent cliff for its HIV medicine Dolutegravir. The shares have performed poorly since our buy tip in May, but the consensus PE of 13 offers a margin of safety compared with pricier pharma companies. Buy. |
Safe haven stock in a recession though |
Doing well so far but US about to open... Will it pare back?! |
Ignore broker ratings for this stock. |
Pick 'n' mix in the broker ratings today...
Stifel raises GSK price target to 1,770 (1,740) pence - 'hold'
DZ Bank cuts fair value for GSK to 1,650 (1,750) pence - 'hold'
JPMorgan cuts GSK price target to 1,550 (1,660) pence - 'underweight' |
That is very good news both for GSK and future patients |
A very nice bit of news here this morning.
Buying just under / just above 1500 seems money well spent here in my opinion.
Good luck all 👍🏻 |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
